IQVIA (NYSE:IQV) Stock Rating Lowered by Wall Street Zen

IQVIA (NYSE:IQV) was downgraded by investment analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a report released on Sunday.

Several other equities analysts have also recently commented on IQV. Truist Financial reissued a “buy” rating and set a $265.00 target price (up previously from $235.00) on shares of IQVIA in a research note on Wednesday, October 29th. JPMorgan Chase & Co. raised their price objective on shares of IQVIA from $177.00 to $255.00 and gave the company an “overweight” rating in a research note on Wednesday, October 29th. Citigroup upped their target price on IQVIA from $200.00 to $230.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 29th. Robert W. Baird set a $258.00 price target on IQVIA and gave the company an “outperform” rating in a research report on Wednesday, October 29th. Finally, Evercore ISI upped their price target on IQVIA from $220.00 to $240.00 and gave the company an “outperform” rating in a report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $239.94.

IQVIA Stock Performance

IQV stock opened at $213.39 on Friday. IQVIA has a 1 year low of $134.65 and a 1 year high of $225.00. The stock has a market capitalization of $36.34 billion, a price-to-earnings ratio of 29.27, a PEG ratio of 2.35 and a beta of 1.34. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.70 and a current ratio of 0.70. The stock’s fifty day moving average is $199.83 and its two-hundred day moving average is $176.94.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Tuesday, October 28th. The medical research company reported $3.00 earnings per share for the quarter, topping analysts’ consensus estimates of $2.98 by $0.02. The business had revenue of $4.10 billion for the quarter, compared to analysts’ expectations of $4.07 billion. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The company’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same quarter last year, the company earned $2.84 EPS. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. On average, research analysts predict that IQVIA will post 10.84 EPS for the current year.

Insider Activity

In related news, insider Eric Sherbet sold 4,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total transaction of $878,800.00. Following the completion of the sale, the insider directly owned 27,108 shares in the company, valued at approximately $5,955,627.60. This trade represents a 12.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 1.60% of the stock is owned by company insiders.

Institutional Investors Weigh In On IQVIA

A number of institutional investors have recently modified their holdings of IQV. Physician Wealth Advisors Inc. increased its stake in shares of IQVIA by 1,340.0% in the third quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock worth $27,000 after acquiring an additional 134 shares during the last quarter. Clal Insurance Enterprises Holdings Ltd grew its stake in IQVIA by 436.7% in the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 131 shares in the last quarter. Westside Investment Management Inc. increased its position in IQVIA by 219.6% in the 3rd quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock worth $30,000 after purchasing an additional 101 shares during the last quarter. AllSquare Wealth Management LLC acquired a new stake in shares of IQVIA during the 1st quarter valued at about $33,000. Finally, Atlantic Union Bankshares Corp bought a new stake in shares of IQVIA in the 3rd quarter valued at approximately $36,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.